$1.88-0.05 (-2.59%)
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
ProKidney Corp. in the Healthcare sector is trading at $1.88. The stock is currently 74% below its 52-week high of $7.13, remaining 21.3% below its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why PROK maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal c...
ProKidney Corp. (NASDAQ:PROK) is one of the best biotech penny stocks to buy in 2026. On March 25, ProKidney appointed Greg Madison as Chief Commercial Officer, a move aimed at preparing the company for the potential launch of its lead cell therapy, rilparencel. Reporting to CEO Bruce Culleton, M.D., Madison is tasked with shaping the […]
Over the last 7 days, the U.S. market has risen by 1.9%, contributing to a 24% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In such a thriving market, identifying stocks with solid financial foundations and growth potential is key for investors looking to capitalize on emerging opportunities. While penny stocks may seem like an outdated concept, they continue to offer access to smaller or newer companies that can provide both affordability...
ProKidney Corp. (NASDAQ:PROK) is one of the 10 best penny stocks that could triple your money. On March 19, ProKidney Corp. (NASDAQ:PROK) announced fourth-quarter revenue of $893,000 against consensus estimates of $600,000. The company provided updates on its clinical progress and strategic priorities for advancing rilparencel through regulatory pathways. Chief Executive Officer Bruce Culleton stated […]
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of -175.08% and -13.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -100.00% and -2.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?